On Nov. 23, 2016, Canopy Growth Corporation (TSX:CGC) announced that Bedrocan Canada, one of its subsidiaries, had completed its first export of medical cannabis to South America, sending 10 kg of dried cannabis to Brazil for the research and development of cannabis-based therapeutics in the country.
“Brazil is an exciting international market for us,” said Bruce Linton, Chairman and CEO of Canopy Growth. “Research will form the basis of a broader medicinal cannabis regime in the country and we are proud to be driving this innovation forward.”
Canopy entered into a partnership with Entourage Phytolab in São Paulo to create Bedrocan Brasil, a company formed to facilitate the importation of Bedrocan Canada’s proprietary cannabis strains, enabling Entourage Phytolab to conduct R&D into cannabis-based therapeutics for the Brazilian market and beyond.
With Bedrocan’s product in hand, Entourage can now prep for a clinical study and develop the stable formulations required to register a new drug candidate with ANVISA, Brazil’s National Health Surveillance Agency. The company is working on a whole-plant drug candidate to target epilepsy and pain management and anticipates registering its candidate in 2018.
Brazil legalized cannabidiol on Jan. 15, 2015, to treat multiple sclerosis, epilepsy and schizophrenia.